Ulixacaltamide, an essential tremor agent, continues to produce encouraging results in the Essential1 study.

Published Date: 13 Aug 2023

After 14 weeks, patients who kept up active treatment during the open-label extension continued to see improvements in their condition.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?

2.

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

3.

For patients with prostate cancer, long-term follow-up helps identify treatment side effects.

4.

Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?

5.

Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot